RxDoctor Payments Data

Hector Descamps

Adult Health · Miami, FLNPI 1902851751

Payments from drug & device makers

$2,582in general payments, 2019–2025

Across 135 payments — averaging $19.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$580
  • AstraZeneca$396
  • Kowa Pharmaceuticals America, Inc.$314
  • Nestle Healthcare Nutrition Inc.$285
  • Aimmune Therapeutics, Inc.$242
  • Amarin Pharma, Inc.$160
  • plus $605 from 7 others

What the payments were for

  • Food & beverage$2,582100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,582 in reported general payments places this provider in the 80th percentile of 2,237 adult health providers in Florida.

See all adult health providers in Florida

Medicare billing

Part B allowed, 2024
$217,434
Medicare patients
137
Services billed
3,528

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ZenpepLipase/Protease/Amylase65$210,500
CreonLipase/Protease/Amylase82$202,563
LinzessLinaclotide220$145,492
VascepaIcosapent Ethyl309$134,675
OzempicSemaglutide60$100,702
EliquisApixaban81$50,534
EntrestoSacubitril/Valsartan60$44,648
Diclofenac Sodium108$32,183
FarxigaDapagliflozin Propanediol55$31,277
XareltoRivaroxaban42$28,039
Combivent RespimatIpratropium/Albuterol Sulfate34$24,745
Repatha SureclickEvolocumab24$21,796
JardianceEmpagliflozin27$21,006
NamzaricMemantine Hcl/Donepezil Hcl16$19,068
Praluent PenAlirocumab30$18,851

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess, Namzaric, Restasis Multidose, Lumigan$580$382,132341 claims
Aimmune Therapeutics, Inc.Zenpep$242$210,50065 claims
Novo NordiskOzempic$114$100,70260 claims
AstraZenecaFarxiga, Breztri Aerosphere$396$47,10183 claims
NovartisEntresto$123$44,64860 claims
Johnson & JohnsonXarelto, Invokana$74$34,45954 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,237 adult health providers in Florida.

Other adult health in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →